How To Approach “Extraordinarily Risky” Clinical-Stage Biotech Stocks
“Investing in any kind of stock can be risky. But investing in clinical-stage biotech stocks can be extraordinarily risky,” acknowledge the authors of today’s article.…
“Investing in any kind of stock can be risky. But investing in clinical-stage biotech stocks can be extraordinarily risky,” acknowledge the authors of today’s article.…
“With West Texas Intermediate (WTI) crude trading near the $60 a barrel level, and expected to go even higher this summer, these could all have…
In screening for stocks with the potential of generating solid returns, the author of today’s article uses a high earnings yield as their primary criterion,…
The company featured in today’s article is creating innovative platforms for performing the next generation of minimally invasive surgical procedures in the brain – and…
“Scared money runs and misses out on profits, while smart money is always poised to pounce on temporary disconnects,” declares the author of today’s article…
“As corporate budgets start to thaw this year along with a gradually reopening economy, AI applications are expected to receive plenty of attention,” notes the…
With a portfolio currently comprised of 45 commercial products and five developmental-stage candidates in various areas, including rare disease and neurology, the company featured in…
On the heels of the news of Roche acquiring GenMark Diagnostics, the author of today’s article shares two more leading diagnostics companies that he believes are prime…
“These are five stocks for aggressive investors looking to get share count leverage on companies that have sizable upside potential,” says the author of today’s…
“With a huge tailwind from the massive stimulus program and the reopening of the economy as spring begins, now is the time to move from…